Trial Profile
TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms TMB-H basket TR
- 21 Jun 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 21 Jun 2022 Status changed from recruiting to not yet recruiting.
- 30 Jul 2021 Planned End Date changed from 13 Sep 2023 to 31 Mar 2025.